LON:STX - Shield Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started GBX 112.50 +4.00 (+3.69 %) (As of 05/26/2019 02:12 PM ET)Previous CloseGBX 112.50Today's RangeGBX 108.60 - GBX 11452-Week RangeGBX 24 - GBX 111Volume133,406 shsAverage Volume48,665 shsMarket Capitalization£131.73 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartInsider TradesHeadlinesOptions Chain Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Shield Therapeutics plc, a specialty pharmaceutical company, in the development and commercialization of hospital-focused pharmaceuticals to treat unmet medical needs. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease. Its advanced pipeline asset is PT20, a novel therapy that has completed its Phase IIb pivotal clinical trial for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also develops PT30 and PT40 intravenous iron formulations. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom. Receive STX News and Ratings via Email Sign-up to receive the latest news and ratings for STX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolLON:STX Previous Symbol CUSIPN/A CIKN/A Webhttp://www.shieldtherapeutics.com/ Phone+44-191-5118500Debt Debt-to-Equity RatioN/A Current Ratio4.21 Quick Ratio4.17Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales£11.88 million Price / Sales11.09 Cash FlowGBX 9 per share Price / Cash Flow12.50 Book ValueGBX 34.70 per share Price / Book3.24Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees15 Outstanding Shares117,089,000Market Cap£131.73 million Next Earnings DateN/A OptionableOptionable Shield Therapeutics (LON:STX) Frequently Asked Questions What is Shield Therapeutics' stock symbol? Shield Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "STX." What price target have analysts set for STX? 2 analysts have issued 1 year price objectives for Shield Therapeutics' stock. Their predictions range from GBX 88 to GBX 200. On average, they anticipate Shield Therapeutics' share price to reach GBX 134.67 in the next year. This suggests a possible upside of 19.7% from the stock's current price. View Analyst Price Targets for Shield Therapeutics. What is the consensus analysts' recommendation for Shield Therapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shield Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Shield Therapeutics. Has Shield Therapeutics been receiving favorable news coverage? Headlines about STX stock have been trending negative this week, according to InfoTrie. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Shield Therapeutics earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an effect on the company's share price in the near future. Who are some of Shield Therapeutics' key competitors? Some companies that are related to Shield Therapeutics include HLS Therapeutics (HLS), HLS Therapeutics (HLS), Benchmark (BMK), ICC Labs (ICC), Depomed (ASRT), WeedMD (WMD), Harvest One Cannabis (HVT), Althea Group (AGH), Delta 9 Cannabis (NINE), Auscann Group (AC8), Biosyent (RX), Probiotec (PBP), Eve & Co Inc (EVE), Invion (IVX) and InMed Pharmaceuticals (IN). What other stocks do shareholders of Shield Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Shield Therapeutics investors own include AcelRx Pharmaceuticals (ACRX), Rockwell Medical (RMTI), Cara Therapeutics (CARA), Caladrius Biosciences (CLBS), Cellectis (CLLS), Geron (GERN), Tungsten (TUNG), Integumen (SKIN), Seeing Machines (SEE) and Skinbiotherapeutics (SBTX). Who are Shield Therapeutics' key executives? Shield Therapeutics' management team includes the folowing people: Mr. Carl Sterritt, Co-Founder, CEO & Director (Age 51)Mr. Timothy William Watts, Chief Financial Officer (Age 61)Fleur Wood, Director of Investor RelationsMs. Lucy Bailey, Gen. Counsel & Company Sec.Ms. Suzanne Wood, Group HR Director How do I buy shares of Shield Therapeutics? Shares of STX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Shield Therapeutics' stock price today? One share of STX stock can currently be purchased for approximately GBX 112.50. How big of a company is Shield Therapeutics? Shield Therapeutics has a market capitalization of £131.73 million and generates £11.88 million in revenue each year. Shield Therapeutics employs 15 workers across the globe. What is Shield Therapeutics' official website? The official website for Shield Therapeutics is http://www.shieldtherapeutics.com/. How can I contact Shield Therapeutics? Shield Therapeutics' mailing address is 3rd Fl Baltic Business Quarters, Abbott's Hill, GATESHEAD, NE8 3D, United Kingdom. The company can be reached via phone at +44-191-5118500. MarketBeat Community Rating for Shield Therapeutics (LON STX)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 166 (Vote Outperform)Underperform Votes: 119 (Vote Underperform)Total Votes: 285MarketBeat's community ratings are surveys of what our community members think about Shield Therapeutics and other stocks. Vote "Outperform" if you believe STX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/26/2019 by MarketBeat.com StaffFeatured Article: What is a Special Dividend? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.